In 2018, the US Food and Drug Administration (FDA) approved or added additional indications to 47 oncology medications or biologics, while the FDA has already approved 20 oncology drugs or biologics in 2019. The drug-development process, which could lead to approval, is lengthy and involves numerous procedures to guarantee that the medication is both safe and effective. We will make a greater contribution to the advancement of this session.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
